Osteopore Ltd. · ASX:OSX
Osteopore — Investor Presentation (February 2023)
28 slides from Osteopore's investor presentation, Feb 20, 2023
Slide 1: Investor Presentation 2023
For personal use only INVESTOR PRESENTATION 2023 ASX: OSX
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to con tain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not t
Slide 3: Mission, Vision, Impact
For personal use only MISSION Harness our superior technology to become the standard of care globally for natural tissue regeneration. VISION To be the most valuable regenerative medical technology company in the world. IMPACT Improve clinical outcomes and patient quality-of-life, and reduce overall
Slide 4: Established pedigree, breakthrough technology, superior results
For personal use only ESTABLISHED PEDIGREE BREAKTHROUGH TECHNOLOGY SUPERIOR RESULTS Osteopore is recognised as a Our novel implants empower Proven to be a more effective global leader in regenerative natural bone regeneration and treatment than traditional bone medical technology and devices. dissol
Slide 5: ASX Regenerative Medtech Landscape and Capital Structure
ASX REGENERATIVE MEDTECH LANDSCAPE $1.55bn For personal use only $744.49m CAPITAL STRUCTURE Shares on Issue A 123.9m $375.70m Total Options on Issue B 3.2m $41.44m $36.80m $74.93m Market Cap @ A$0.12 C A$14.9m $14.87m $43.69m $14.82m $1.11m $0m $1.47m EV @ A$0.12 C A$13.6m CASH BALANCE D A$1.3m Dec
Slide 6: Our implants are the 'first of its kind'
OUR IMPLANTS ARE THE ‘FIRST OF ITS KIND’ For personal use only PROPRIETARY TECHNOLOGY IMPROVES LIVES MULTIPLE APPLICATIONS Breakthrough 3D printed Only biomimetic scaffold available HIGH USE IMPLANTS implants that facilitate that naturally dissolves over time. • Multiple off-the-shelf implants natur
Slide 7: We deliver superior patient outcomes
WE DELIVER SUPERIOR PATIENT OUTCOMES For personal use only PERMANENT IMPLANTS BONE GRAFT US$100BN MARKET 1 US$3.9BN MARKET 2 25-33% 6-19% 0.01% Complication Complication Complication Rates 3,4,5 Rates 6,7,8 Rate Superior, commercially ready Permanent implants are The ‘gold standard’ bone graft produ
Slide 8: Osteopore is ahead of the competition
For personal use only Microporous (Biomimetic Structure) OSTEOPORE IS AHEAD OF THE MedPor (Stryker) COMPETITION There are no other FDA or CE Mark cleared products that offer Osteopore’s key technology characteristics Anatomics – bio-resorption and biomimetic structure - which AccuShape (MedCad) Rapi
Slide 9: Our technology is validated
For personal use only OUR TECHNOLOGY IS VALIDATED Regulatory clearances secured in most major markets, including FDA (U.S.), CE Mark (European Union), TGA (Australia), HSA (Singapore), and more. Over 80,000 successful cases with superior results over traditional procedures. Products marketed and sol
Slide 10: Several world's first - life changing clinical outcomes
SEVERAL WORLD’S FIRST - LIFE CHANGING CLINICAL OUTCOMES For personal use only Largest ever reconstruction Bone reconstruction of a segmental bone defect 1 after cancer treatment 36cm tibia 15cm Post-Cancer Tibia reconstruction in 2017. Reconstruction to save her leg from amputation. Incredible recov
Slide 11: Recent achievements
RECENT ACHIEVEMENTS For personal use only Multiple distribution agreements signed Achieved initial first sales Achieved highest calendar year revenue in the company's history A$1.69M CY22 Malaysia4 Australia5 Colombia1 Spain2 +52% CY 2021 New Zealand5 U.S.6 South Africa3 U.S. Distribution agreement
Slide 12: Our key business - Craniofacial
OUR KEY BUSINESS - CRANIOFACIAL For personal use only Product Example Product Example Orbital Floor Reconstruction Craniotomy Delivers structural support and predictable Allows for the full restoration of patients’ skull bone regeneration for orbital floor fractures contours in post-craniotomy proce
Slide 13: Our key markets - Aesthetic
OUR KEY MARKETS - AESTHETIC For personal use only Product Example Septal Extension Grafting & Nasal Tip Plasty Provides good structural support to achieve long-term aesthetically pleasing nose augmentation outcomes ACHIEVEMENTS TO DATE PRIORITIES FOR 2023 Cumulative over 48,000 implants since 2017 E
Slide 14: Our key markets - Dental / OMF
OUR KEY MARKETS - DENTAL / OMF For personal use only Product Example Product Example Socket Preservation Guided Bone Regeneration Implant to preserve dental socket after tooth Provides support of graft material, delivering extraction and support the dental implant a predictable shape to regenerate b
Slide 15: Our key markets - Orthopaedic
OUR KEY MARKETS - ORTHOPAEDIC For personal use only Product Example Product Example High Tibial Osteotomy (HTO) Long bone reconstruction Implant to correct angulation of the knee Implant that is combined with bone graft and to provide to delay progression of osteoarthritis mechanical support in larg
Slide 16: Commercial priorities
COMMERCIAL PRIORITIES For personal use only EXPANDING SALES GAINING FURTHER Further sales distribution agreements REGULATORY ACCESS anticipated to be secured throughout Regulatory clearances already secured in 2023, and investigating potential many major markets, with multiple clinical partnerships
Slide 17: Encouraging organic revenue growth
ENCOURAGING For personal use only ORGANIC REVENUE GROWTH $500 QUARTERLY SALES REVENUE IN SGD (THOUSAND) $461 $450 $422 $431 Highly encouraging commercial outlook with organic $391 $400 $358 revenue growth expected to be boosted by increased $372 $348 revenue and margins from Osteopore’s recent acqui
Slide 18: Proposed acquisition to boost revenue
Direct Model DIRECT TO CUSTOMER MODEL For personal use only PROPOSED ACQUISITION Acquisition expected to add immediate additional revenue to our TO BOOST REVENUE 1 top line. Increased margins will be achieved by selling fully priced products direct to customers. Osteopore has entered into a binding
Slide 19: Three areas we are focused on for 2023
THREE AREAS WE ARE For personal use only FOCUSED ON FOR 2023 GROW REVENUE Continue to pursue organic growth in existing markets. Launch products in new markets such as orthopaedic and dental to generate additional revenue stream. PARTNERSHIPS Partnering with industry peers to cross sell products tha
Slide 20: Current global sales for first generation product
For personal use only Israel China CURRENT GLOBAL Japan SALES FOR FIRST Egypt GENERATION PRODUCT Brazil Jordan Current countries with sales Near term additional target markets America Europe Australia Singapore Korea Philippines OSTEOPORE.COM 20
Slide 21: 3D printed implants proprietary technology improving our technology
3D PRINTED IMPLANTS PROPRIETARY TECHNOLOGY IMPROVING OUR For personal use only TECHNOLOGY DESIGN CENTRE OF EXCELLENCE Co-localisation of high value design workflow within vicinity of key university and hospital ecosystems for increased touch-points with key clinicians. Rapid design, manufacturing &
Slide 22: Developing new applications
DEVELOPING NEW APPLICATIONS To stay ahead of the competition and bring innovation to the surgical community For personal use only ORAL Product Clinical Regulatory DENTAL Product R&D Preclinical Research Clinical Trials Regulatory Approvals Initial Sales MAXILLOFACIAL R&D Preclinical Research Trials
Slide 23: Future horizons research programs
FUTURE HORIZONS RESEARCH PROGRAMS For personal use only ACCELERATING BONE REGENERATION OF OTHER PRODUCTS FOR REGENERATION TISSUE TYPES VETERINARY MARKETS Osteopore is developing materials Developing new implant scaffolds Developing surgical applications for to accelerate bone regeneration; to regene
Slide 24: Future milestones
FUTURE MILESTONES For personal use only Q1 Q2 Q3 Q4 Overview of typical SALES NETWORK EXPANSION CY23 CY23 CY23 CY23 pre-sales milestones USA West Coast (Idaho, California) Application of USA East Coast (Georgia, Florida) reimbursement / insurance cover USA Northeast (New York, Boston, Minneapolis) H
Slide 25: Highly credentialed team
HIGHLY CREDENTIALED TEAM For personal use only MARK LEONG PROF TEOH SWEE HIN DANIEL OW GOH KHOON SENG LIM JING, PHD PAUL TURNER EXECUTIVE CHAIRMAN NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR CEO COO & CTO COUNTRY MANAGER, AUSTRALIA Corporate and capital Adjunct Professor NTU, Experienced finance M
Slide 26: Investment highlights
INVESTMENT HIGHLIGHTS For personal use only Breakthrough technology fully validated, offering a lower risk profile Proven, superior products compared to bone grafts and permanent implants Encouraging commercial outlook with sales and global presence increasing Innovative research programs could pres
Slide 27: For personal use only
For personal use only Mark Leong Executive Chairman E: mark_leong@osteopore.com Goh Khoon Seng Chief Executive Officer E: goh_khoon_seng@osteopore.com Lim Jing Chief Operating Officer | Chief Technology Officer E: lim_jing@osteopore.com
Slide 28: Sources
SOURCES For personal use only 1 Allied Market Research - Permanent Implant Sales 2 BCC Research - Bone Graft Substitutes Market by 2025 3 Giese, H., Meyer, J., Unterberg, A., & Beynon, C. (2020). Long-term complications and implant survival rates after cranioplastic surgery: a single-center study of